Nymox Pharmaceutical's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nymox Pharmaceutical (NYMX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nymox Pharmaceutical vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 5M combined for its competitors (0.1% combined share).
- Peer differentiation: Revenue per employee of $0.00M compares with $0.06M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Nymox Pharmaceutical vs. its Competitors, Q4 2024
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Nymox Pharmaceutical reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Nymox Pharmaceutical and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Nymox Pharmaceutical Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Nymox Pharmaceutical's competitor groups requires a Commercial License.
Nymox Pharmaceutical's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nymox Pharmaceutical Corporation | - | - | - | Yes |
| Competitors combined (3) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NYMX Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ocugen Inc | 282.9% | Outperformed |
| 2 | Atossa Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nymox Pharmaceutical's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Nymox Pharmaceutical's Comment on Competition and Industry Peers
Publicly Traded Peers of Nymox Pharmaceutical Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nymox Pharmaceutical Corporation |
18.73 | 0.01 |
 Ocugen Inc |
313.28 | 4.58 |
 Atossa Therapeutics Inc |
18.89 | - |
 Athersys Inc |
0.00 | 5.33 |
| SUBTOTAL | 350.90 | 9.91 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nymox Pharmaceutical Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nymox Pharmaceutical's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nymox Pharmaceutical Corporation | 19 | 208 | -187,167 |
| Ocugen Inc | 313 | 39,483 | -705,267 |
| Atossa Therapeutics Inc | 19 | - | -2,356,812 |
| Athersys Inc | 0 | 123,837 | -872,256 |
| PEERS TOTAL | 332 | 56,600 | -897,297 |
Nymox Pharmaceutical's Position in Industry Market Structure
Market-capitalization share and concentration across all 18 companies in Nymox Pharmaceutical's industry classification, broader than the peer set above. Market cap in millions of $.Nymox Pharmaceutical ranks #0 of 18 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 5,928, indicating a highly concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Idexx Laboratories Inc | 53,618 | 76.17 % |
| 2 | Lantheus Holdings Inc | 6,793 | 9.65 % |
| 3 | Neogen Corporation | 2,558 | 3.63 % |
| 4 | Celldex Therapeutics inc | 2,325 | 3.30 % |
| 5 | Intellia Therapeutics Inc | 1,234 | 5.2% |
| 6 | Trinity Biotech Plc | 1,234 | 5.2% |
| 7 | Quidelortho Corp | 1,234 | 5.2% |
| 8 | Achieve Life Sciences Inc | 1,234 | 5.2% |
| 9 | Myriad Genetics Inc | 1,234 | 5.2% |
| 10 | Alpha Teknova Inc | 1,234 | 5.2% |
| 0 | Nymox Pharmaceutical Corporation | 19 | 0.00 % |
Market cap and industry share for the rest of Nymox Pharmaceutical's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2023-07-06.
Nymox Pharmaceutical's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | - | - |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nymox Pharmaceutical's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 5,928 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Nymox Pharmaceutical's dedicated Suppliers and Customers pages, not here.
Nymox Pharmaceutical's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Idexx Laboratories Inc, holding 76.17 % of industry market cap.
- Tracked peer group's revenue run-rate is broadly decelerating (-33.3% annualized).
Methodology: see Methodology: SWOT Analysis.
Nymox Pharmaceutical's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nymox Pharmaceutical Corporation | 0.01 | 0.09 | - |
| Ocugen Inc | 0.93 | 1.05 | - |
| Atossa Therapeutics Inc | 5.15 | 5.75 | - |
| Athersys Inc | 0.09 | 0.17 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nymox Pharmaceutical's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nymox Pharmaceutical Corporation | Q4 2024 | - | - |
| Ocugen Inc | Q2 2026 | +8.4 % | - |
| Atossa Therapeutics Inc | Q2 2026 | - | - |
| Athersys Inc | Q3 2023 | - | - |
| PEERS TOTAL | +3.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nymox Pharmaceutical's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nymox Pharmaceutical Corporation | Q4 2024 | - | - |
| Ocugen Inc | Q2 2026 | - | -51.2 % |
| Atossa Therapeutics Inc | Q2 2026 | - | - |
| Athersys Inc | Q3 2023 | - | - |
Nymox Pharmaceutical's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nymox Pharmaceutical Corporation | - | - | - |
| Ocugen Inc | - | - | - |
| Atossa Therapeutics Inc | - | - | - |
| Athersys Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nymox Pharmaceutical's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nymox Pharmaceutical Corporation | - | 3,746.84 |
| Ocugen Inc | - | 68.40 |
| Atossa Therapeutics Inc | - | - |
| Athersys Inc | - | 0.00 |
| PEERS AVERAGE | - | 35.41 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.